Table 2.
Immunological parameters and clinical outcomes of the liver-inclusive versus the liver-exclusive allograft
| Clinical characteristics | All patients (n =212) | Liver-exclusive (n =136) | Liver-inclusive (n =76) | p-value |
|---|---|---|---|---|
| Number of HLA mismatches | ||||
| Class I (A, B locus) | 2.9 ± 1.0 | 2.9 ± 1.0 | 2.8 ± 1.1 | NS |
| Class II (DR locus) | 1.6 ± 0.5 | 1.6 ± 0.5 | 1.6 ± 0.5 | NS |
| PRA HLA class I (%) | 21.8 ± 32.1 | 20.7 ± 30.7 | 23.8 ± 34.6 | NS |
| PRA HLA class II (%) | 16.2 ± 29.6 | 16.8 ± 30.4 | 15.1 ± 28.3 | NS |
| Positive cross-match, n (%) | 55 (25.9) | 34 (25.0) | 21 (27.6) | NS |
| Preformed DSA, n (%) | 44/154 (28.6) | 30/99 (30.3) | 14/55 (25.5) | NS |
| De novo DSA, n (%) | 35/154 (22.7) | 28/99 (28.3) | 7/55 (12.9) | 0.03 |
| Acute rejection (≤ 360 days), n (%) | 133 (62.7) | 92 (67.6) | 41 (53.9) | 0.05 |
| Acute ABMR, n (%) | 17/154 (11.0) | 15/99 (15.2) | 2/55 (3.6) | 0.03 |
| ACR, n (%) | 116 (54.7) | 77 (56.6) | 39 (51.3) | NS |
| Mild | 91 (42.9) | 58 (42.6) | 33 (43.4) | 0.91 |
| Moderate | 54 (25.5) | 42 (30.9) | 12 (15.8) | 0.02 |
| Severe | 35 (16.5) | 29 (21.3) | 6 (7.9) | 0.01 |
| Median first acute rejection, months | 1.0 (0.1–35.4) | 0.8 (0.5–35.4) | 1.6 (0.1–31.3) | NS |
| Chronic rejection, n (%) | 36 (17.0) | 33 (24.3) | 3 (3.9) | 0.0002 |
| Causes of graft failure, n (%) | 89 (42.0) | 56 (41.2) | 33 (43.4) | NS |
| Rejection | 47 (22.2) | 42 (30.9) | 5 (6.6) | <0.0001 |
| Infection | 26 (12.3) | 7 (5.1) | 19 (25.0) | <0.0001 |
| Technical | 4 (1.9) | 1 (0.7) | 3 (3.9) | NS |
| Primary-non-function | 1 (0.5) | 0 | 1 (1.3) | NS |
| Graft-versus-host disease | 1 (0.5) | 0 | 1 (1.3) | NS |
| Neoplasm | 1 (0.5) | 0 | 1 (1.3) | NS |
| Others | 4 (1.9) | 3 (2.2) | 0 | NS |
| Unknown | 6 (2.8) | 3 (2.2) | 3 (3.9) | NS |
| Retransplantation, n (%) | 24 (11.3) | 22 (16.2) | 2 (2.6) | 0.003 |
| Mortality ≤360 days | 22 (10.4) | 8 (5.9) | 14 (18.4) | 0.004 |
PRA, panel reactive antibody; HLA, human leukocyte antigen; DSA, donor-specific antibody; ACR, acute cellular rejection; ABMR, antibody-mediated rejection; NS, not significant.